SCHEDULE: Coastlands Capital Discloses 9.99% Stake in Pasithea

Coastlands Capital LP and its affiliates have disclosed a 9.99% beneficial ownership stake in Pasithea Therapeutics Corp., comprising common stock and pre-funded warrants.

Summary

• Coastlands Capital LP, along with its affiliated entities Coastlands Capital Partners LP, Coastlands Capital GP LLC, Coastlands Capital LLC, and Matthew D. Perry, collectively reported beneficial ownership of 2,394,765 shares of Pasithea Therapeutics Corp. common stock.
• This aggregate amount represents 9.99% of Pasithea Therapeutics Corp.'s outstanding common stock.
• The ownership consists of 1,514,199 shares of Common Stock held directly by Coastlands Capital LP and 880,566 shares of Common Stock issuable upon the exercise of pre-funded warrants held by Coastlands Capital LP.
• The calculation of beneficial ownership is based on 23,091,062 shares outstanding as of December 22, 2025, as disclosed in Pasithea's definitive proxy statement on DEF 14A filed on December 29, 2025.
• The reported percentage reflects a beneficial ownership limitation of 9.99%, with pre-funded warrants in excess of this limitation being excluded from the calculation.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Pasithea Therapeutics Corp.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, as a significant institutional stake can be a vote of confidence, though the passive nature and beneficial ownership limitation temper the immediate impact.

Positives

• A significant stake by an institutional investor like Coastlands Capital can signal confidence in Pasithea Therapeutics Corp.'s long-term prospects.
• The acquisition is stated to be in the ordinary course of business, suggesting a passive investment rather than an activist intent that could create uncertainty.

Negatives

• The beneficial ownership limitation of 9.99% suggests that Coastlands Capital may hold additional pre-funded warrants that are not currently exercisable to avoid exceeding this threshold, which could indicate a strategic cap on their immediate influence or a regulatory consideration.

Risks

• No specific risks for Pasithea Therapeutics Corp. are mentioned in this Schedule 13G filing, as it primarily concerns the beneficial ownership disclosure of the reporting persons.

Future Outlook

This filing does not contain any forward-looking statements or guidance from Pasithea Therapeutics Corp. or the reporting persons regarding the issuer's future performance.

Industry Context

StockSavvy.ai notes that a significant passive stake, such as the 9.99% reported by Coastlands Capital, is a common occurrence in the investment landscape. While not indicative of an activist position, it signals an institutional investor's belief in the company's value proposition. For a company like Pasithea Therapeutics, operating in the potentially volatile biotechnology or pharmaceutical sector, such an investment can provide a degree of stability and validation from the investment community.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor holding a near-10% stake could be viewed positively, potentially increasing investor confidence and market liquidity for Pasithea Therapeutics Corp. common stock.

Key Dates

Keywords

Pasithea Therapeutics Corp., Coastlands Capital LP, Beneficial Ownership, Schedule 13G, Common Stock, Pre-funded Warrants, Institutional Investor, Equity Stake, PTHE